NCT05918068 is a NA clinical trial of Metformin 500 mg/day in Diabetes Mellitus, Type 2, sponsored by Al-Rasheed University College.

Who is sponsoring NCT05918068?

NCT05918068 is sponsored by Al-Rasheed University College.

What drugs are being tested in NCT05918068?

Interventions in NCT05918068: Metformin 500 mg/day, Metformin 500 mg/day plus vitamin B6 300 mg/day, non-pharmacological therapy.

What condition does NCT05918068 study?

NCT05918068 studies Diabetes Mellitus, Type 2.

Is NCT05918068 still recruiting?

NCT05918068 is currently completed. Last updated 26 June 2023.

Last reviewed 2023-06-26 · How we verify

NCT05918068

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pyridoxine Effect on the Blood Glucose Level in Type 2 Diabetic Patients

Completed NA Last updated 26 June 2023

What this trial tests

NA trial testing Metformin 500 mg/day in Diabetes Mellitus, Type 2 in 108 participants. Completed in 1 April 2023.

Timeline

1 November 2022

Primary endpoint
1 April 2023

1 April 2023

Quick facts

Lead sponsor	Al-Rasheed University College
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	108
Start date	1 November 2022
Primary completion	1 April 2023
Estimated completion	1 April 2023
Sites	1 location across Iraq

Drugs / interventions tested

Metformin 500 mg/day — full drug profile →
Metformin 500 mg/day plus vitamin B6 300 mg/day
non-pharmacological therapy

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Al-Rasheed University College

Who can join

Adults 30 to 65, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pyridoxal-5-phosphate (P.L.P.), the biologically active form of vitamin B6, is a coenzyme in 150 enzymatic reactions, including amino acid, carbohydrate, and lipid metabolism. Neurotransmitter production and breakdown depend on it. Additionally, it functions as an antioxidant by suppressing reactive oxygen species and mitigating the development of advanced glycation end products. Humans recycle P.L.P. from dietary B6 vitamins, and this molecule has been related to various clinically relevant diseases. Pyridoxine as an additional therapy for type 2 diabetes will be examined in this study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Al-Rasheed University College trials

Trials by the same sponsor.

NCT06549556 — The Value of Using Colostrum Supplements on the Physical Performance and Cognitive Function in Healthy Subjects and Type · Phase 2 · completed
NCT05981742 — Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activiti · Phase 2 · completed
NCT06022640 — Educational and Supportive Care to Depressed Infertile Females · NA · completed
NCT04348006 — Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients · Phase 4 · withdrawn
NCT06454643 — Gentamicin in Cardiac Surgery · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05918068 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Al-Rasheed University College
Last refreshed: 26 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05918068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing